HSBC Holdings’s Novavax NVAX Stock Holding History

HSBC Holdings’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,000,000	Closed	-$147M	–	3415
2021 Q4	$147M	Buy	+1,000,000	New	+$172M	0.14%	127

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HSBC Holdings's NVAX Position: Q1 2026 in Review

HSBC Holdings reduced its Novavax (NVAX) stake by 68% in Q1 2026, selling an estimated $364K and leaving 18,628 shares worth $149K. The position accounts for ﹤0.01% of the portfolio, ranked #2683.

HSBC Holdings first reported a position in NVAX in Q4 2014 and has held it in 27 quarters since. The position peaked at $148M in Q4 2021. 258 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

HSBC Holdings held 18,628 shares of Novavax worth $149K as of Q1 2026.
HSBC Holdings sold 40,153 Novavax shares in Q1 2026, an estimated $364K.
Novavax made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2683 holding.
HSBC Holdings first reported a position in Novavax in Q4 2014 and has held it in 27 quarters since.
HSBC Holdings's Novavax position peaked at $148M in Q4 2021.
258 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.